The mechanistic basis for the disparate effects of angiotensin II on coronary collateral growth.
OBJECTIVE
We hypothesize that controversial effects of angiotensin II (Ang II) are attributable to its regulation of reactive oxygen species (ROS) and ROS-dependent signaling.


RESULTS
Coronary collateral growth (CCG) was stimulated in normal (WKY) and syndrome X (JCR) rats by transient/repetitive ischemia (RI). Blood flow was measured in the normal (NZ) and the collateral-dependent (CZ) zone. In WKY, RI increased CZ flow (0.84 mL/min/g), but RI+subpressor Ang II increased it more (1.24 mL/min/g). This was associated with transient p38 and sustained Akt activation. A hypertensive dose of Ang II decreased CZ flow (0.69 mL/min/g), which was associated with sustained p38 and transient Akt activation. AT1R blockade by candesartan abrogated CZ flow in WKY (0.58 mL/min/g), reduced myocardial superoxide, and blocked p38 and Akt activation. RI-induced CZ flow in JCR was significantly decreased compared with WKY (0.12 mL/min/g), associated with a large increase in superoxide and lack of p38 and Akt activation. CZ flow in JCR was partially restored by candesartan (0.45 mL/min/g), accompanied by reduction in superoxide and partial restoration of p38 and Akt activation.


CONCLUSIONS
Ang II/AT1R blockade, at least in part, regulates CCG via generating optimal ROS amounts and activating redox-sensitive signaling.
Reed
Ryan
R
Department of Integrative Medical Sciences, Northeastern Ohio Universities College of Medicine, 4209 State Route 44, PO Box 95, Rootstown, OH 44275, USA.
Kolz
Christopher
C
Potter
Barry
B
Rocic
Petra
P
D000804:Angiotensin II / Q000502:physiology*; D000818:Animals; D054059:Coronary Occlusion / Q000188:drug therapy / Q000503:physiopathology*; D004195:Disease Models, Animal; D018056:Hemorheology; D007511:Ischemia / Q000188:drug therapy / Q000503:physiopathology*; D008297:Male; D018919:Neovascularization, Physiologic / Q000502:physiology*; D018384:Oxidative Stress / Q000502:physiology*; D051381:Rats; D017382:Reactive Oxygen Species / Q000009:adverse effects / Q000378:metabolism; D044140:Receptor, Angiotensin, Type 1 / Q000187:drug effects* / Q000502:physiology; D014662:Vasoconstrictor Agents / Q000494:pharmacology
D017382:Reactive Oxygen Species; D044140:Receptor, Angiotensin, Type 1; D014662:Vasoconstrictor Agents; D000804:Angiotensin II